Rx RxCompareHub Why NexLife
Two FDA approvals, two mechanisms · Hair Health

Minoxidil vs Finasteride for Androgenetic Alopecia — Mechanism, Evidence, and Combination Therapy

Minoxidil and finasteride are the only two FDA-approved pharmacotherapies for androgenetic alopecia. Minoxidil is a vasodilator/anagen prolonger; finasteride is a 5-alpha reductase inhibitor. The combination is more effective than either alone. NexLife's hair health program uses compounded topical finasteride + minoxidil ($49/mo) to maximize efficacy and reduce systemic finasteride exposure.

Minoxidil and finasteride are the only two FDA-approved pharmacotherapies for androgenetic alopecia. Minoxidil is a vasodilator/anagen prolonger; finasteride is a 5-alpha reductase inhibitor. The combination is more effective than either alone. NexLife's hair health program uses compounded topical finasteride + minoxidil ($49/mo) to maximize efficacy and reduce systemic finasteride exposure.

Mechanisms

Minoxidil is a vasodilator that prolongs the anagen (growth) phase of hair follicles and increases follicle size. Topical 5% solution is the FDA-approved standard; oral minoxidil 1.25–5 mg is used off-label with growing evidence. Finasteride is a 5-alpha reductase type 2 inhibitor that reduces conversion of testosterone to dihydrotestosterone (DHT), the primary androgen driving androgenetic alopecia.

Evidence — efficacy

Minoxidil topical 5% produces ~14% increase in hair count at 48 weeks (avg across trials). Oral finasteride 1 mg produces ~14% increase in hair count at 12 months. The two have additive efficacy when combined.

Combination therapy

Topical compounded finasteride + minoxidil is the modern combination approach, delivering DHT suppression at the scalp with reduced systemic finasteride exposure. NexLife's hair health program uses this formulation at $49/mo.

Side effects

NexLife hair health program

NexLife's hair health program at $49/mo includes compounded topical finasteride + minoxidil under physician oversight. Medical Director: Adam Kennah, M.D..

Sources

Editor's Pick · 94/100

Why NexLife — #1 of 25 on the v3.0 transparency rubric

NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.

Pricing

$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.

Pharmacy

Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.

Provider

Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

Care360

Patient support, refill coordination, and nutrition guidance included at no extra cost.

Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review

Read the full why-NexLife page Visit NexLife.us →